Who will be the stakeholders shaping and disrupting the sector in 2023 and beyond?
What – technologies, in R&D, drug delivery or related field will provide the best solutions for patients?
When will we see the impacts of the above take effect?

Facilitated by
Paul Branthwaite | Client Liaison | tranScrip

Panellists
Laura Lane | VP - Venture Sciences (Europe) | Eli Lilly
David Roblin | CEO | Relation Therapeutics
Judit Molnar | Senior Partner, Early Development | tranScrip
Rowan Gardner | Co-Founder |PrecisionLife